Email updates

Keep up to date with the latest news and content from Cardiovascular Diabetology and BioMed Central.

Open Access Original investigation

High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome

Ken Kishida12*, Yasuhiko Nakagawa1, Hironori Kobayashi3, Toru Mazaki4, Hiroyoshi Yokoi4, Koji Yanagi5, Tohru Funahashi16 and Iichiro Shimomura1

Author Affiliations

1 Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan

2 Kishida Clinic, Toyonaka, Osaka, Japan

3 Department of Research and Development, Diagnostic Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Tokushima, Japan

4 Department of Cardiology, Kokura Memorial Hospital, Kokura, Fukuoka, Japan

5 Department of Cardiology, Kenporen Osaka Central Hospital, Osaka, Osaka, Japan

6 Department of Metabolism and Atherosclerlosis, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan

For all author emails, please log on.

Cardiovascular Diabetology 2014, 13:9  doi:10.1186/1475-2840-13-9

Published: 9 January 2014

Abstract

Background

The complement system is part of the immune system in acute coronary syndrome (ACS). Adiponectin has anti-atherogenic and anti-inflammatory properties. Adiponectin and C1q form a protein complex in blood, and serum C1q binding adiponectin (C1q-APN) can be measured. We investigated the comparative evaluation of serum C1q-APN levels in males with ACS, stable angina pectoris (SAP) versus controls.

Methods

The study subjects were 138 Japanese patients who underwent diagnostic coronary angiography. Blood total adiponectin (Total-APN), C1q-APN and C1q were measured by enzyme-linked immunosorbent assays. Patients were divided into three groups according to the clinical condition: ACS (n = 78), SAP (n = 41) or normal coronary (NC, n = 19) groups.

Results

Serum C1q levels were significantly higher in the ACS group (54.9±1.2 μg/mL) than in the NC group (48.0±2.5 μg/mL). Although serum Total-APN levels were significantly lower in the SAP and ACS groups, compared with the NC group (7.0±0.5, 7.2±0.3, 10.6±2.0 μg/mL, respectively), serum C1q-APN levels were significantly higher in the ACS group than in the NC and SAP groups (112.1±4.1, 66.3±4.4, 65.7±2.9 units/mL, respectively).

Conclusions

Patients with ACS had higher serum C1q-APN levels.

Trial Registration

UMIN000002997

Keywords:
Adiponectin; C1q; C1q-binding adiponectin; Acute coronary syndrome